Pages that link to "Q68694042"

The following pages link to Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer (Q68694042):

Displaying 23 items.

• Intraperitoneal drug delivery of antineoplastics (Q34315073) (← links)
• Intraperitoneal antineoplastic drug delivery: rationale and results (Q35121705) (← links)
• The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies (Q35563252) (← links)
• Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer (Q36657495) (← links)
• Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. (Q36840545) (← links)
• Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin (Q37230288) (← links)
• Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics (Q37993908) (← links)
• Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up (Q40100306) (← links)
• "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). (Q41396887) (← links)
• Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation (Q41596840) (← links)
• Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines (Q41615756) (← links)
• Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate (Q43807749) (← links)
• Recurrent gastrointestinal stromal sarcomas (Q47585033) (← links)
• Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease (Q50506495) (← links)
• Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor (Q57846591) (← links)
• Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy (Q67744145) (← links)
• Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone (Q68078593) (← links)
• Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration (Q68100402) (← links)
• Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy (Q68121317) (← links)
• Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer (Q72611365) (← links)
• Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II) (Q72708254) (← links)
• Intraperitoneal Chemotherapy with Mitoxanthrone in Ovarian Cancer (Q74039242) (← links)
• A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer (Q87416739) (← links)